Have an account? Log in.
I don't have an account.
Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $42 to $39.
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.
Conmed (NYSE:CNMD) raises FY2026 sales outlook from $1.345 billion-$1.375 billion to $1.350 billion-$1.375 billion vs $1.359 billion estimate.
Conmed (NYSE:CNMD) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.82 by 8.54 percent. This is a 6.32 percent decrease over earnings of $0.95 per share from the same period